Clinical Trial Update: RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing CD101 to standard of care for acute vulvovaginal candidiasis (yeast infection).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidiasis Vulvovaginal
• Mycoses
• Vaginitis Monilial

Drugs mentioned

• CD101

Snippet

Sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Candidiasis, Vulvovaginal, Mycoses | Phase 2 | Status: COMPLETED